“…[8] Among the hypoxic markers, HIF-1α has been studied commonly either alone or mainly with other markers like HIF-2α, [10,12,13] CA-IX, [10,14,15] GLUT-1, [10,14,16,17] and VEGF. [10,[13][14][15][18][19][20][21] Increased HIF-1α expression has been found to be significantly correlated with clinicopathological variables such as clinical stage, histopathological grade, and lymph node involvement in many studies, [12,14,16,18] with correlation with only clinical stage and lymph node involvement in some, [22][23][24] with tumor size [23,24] and in some even with recurrences. [15,17] The expression of HIF-1α was localized to the nucleus and was distributed heterogeneously throughout the tumor area especially in the perinecrotic regions, and at the tumor/stroma interface.…”